Effects of Pharmacokinetic and Pharmacodynamic Changes in the Elderly
Effects of Pharmacokinetic and Pharmacodynamic Changes in the Elderly
All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
Premiere Date: January 20, 2013
?Expiration Date: January 20, 2014
This activity offers CE credits for:
1. Physicians (CME)
?2. Other
Activity Goal
The goal of this activity is to explain and demonstrate the need for monitoring and altering psychotropic medications and dosages in older patients.
Learning Objectives
At the end of this CE activity, participants should be able to:
1. Appreciate and analyze the pharmacodynamic and
pharmacokinetic changes that occur as patients age.
2. Develop/modify appropriate treatment strategies for older adults based on pharmacodynamic and pharmacokinetic changes.
3. Assess signs of problems associated with medication pharmacodynamics and pharmacokinetics in older patients.
Target Audience
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
Credit Information
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only
the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Sandra Jacobson, MD, has no disclosures to report.
James M. Ellison, MD, (peer/content reviewer) has disclosed that he received research support from Eli Lilly and Company.
Natalie Timoshin has no disclosures to report.
Heidi Anne Duerr has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity?
Call us at 877.CME.PROS (877.263.7767).
Steady state of a drug is better approximated, and more easily, by multiplying the drug's half life by 5: it takes you to about 96% of the theoretical value. This applies when doses are repeated at least daily for drugs with half life of over 24 hours. For drugs with shorter half lives, the levels does not reach steadiness (or rise eventually to undesirable levels) unless the doses are repeated within the half-life period for the drug.
I wonder about the basis for a factor of 4.5